Phakic intraocular lens

PANORAMA EYECARE SPINS OFF NEW LASIK DIVISION AND ANNOUNCES PARTNERSHIP WITH DENVER BRONCOS

Retrieved on: 
Monday, August 8, 2022
Dallas, Rocky Mountains, Eye, Surgeon, Glaucoma, Technology, Bucking horse, Growth, Plastic, Business development, ASC, Phakic intraocular lens, ASC X12, Health, CO, Vance DeGeneres, Denver Broncos, UV, PEC, Partnership, Dallas Cowboys, Fort Collins, Colorado, Corneal cross-linking, MD, OD, SMILE, Panorama, Medical device, Telescopic sight, PRK, LASIK

FORT COLLINS, Colo., Aug. 8, 2022 /PRNewswire/ -- Panorama Eyecare (PEC), a physician-led management services organization and the largest comprehensive eye care organization in the Rocky Mountain region, announces the formation of Panorama LASIK a group of vision correction centers under the Panorama Eyecare. Panorama LASIK will be the LASIK Partner of the Denver Broncos.

Key Points: 
  • Panorama LASIK will be the LASIK Partner of the Denver Broncos.
  • Panorama LASIK launches as a division of Panorama Eyecare and LASIK Partner of the Denver Broncos.
  • Panorama LASIK is a division of the largest comprehensive eye care organization in the Rocky Mountain region, Panorama Eyecare (PEC).
  • Panorama LASIK will debut as the LASIK Partner of the Denver Broncos ahead of the Broncos first preseason game against the Dallas Cowboys on August 13th.

Visus Therapeutics Initiates Phase 2 Clinical Trial of BRIMOCHOL for the Treatment of Presbyopia

Retrieved on: 
Thursday, March 25, 2021
Medical Supplies, Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Research, Science, Clinical trials, Corrective lenses, Eye, Nervous system, Sensory systems, Vision, Disability, Presbyopia, Ophthalmology, Emmetropia, Phakic intraocular lens, Intraocular lens

Presbyopia is the loss of near vision associated with aging, making it difficult to perform certain tasks like reading fine print.

Key Points: 
  • Presbyopia is the loss of near vision associated with aging, making it difficult to perform certain tasks like reading fine print.
  • We have designed a robust clinical development program in a diverse population of patients living with presbyopia.
  • The Phase 2 clinical trial ( NCT04774237 ) is a double-masked, randomized crossover study designed to evaluate the safety and efficacy of two proprietary formulations of BRIMOCHOL topical ophthalmic solution in patients with emmetropic phakic and pseudophakic presbyopia.
  • With offices in Seattle and Orange County, Calif., its lead clinical candidate is BRIMOCHOL, an eye drop designed to correct the loss of near vision associated with presbyopia.

STAAR Surgical Announces the EVO Implantable Lens US Clinical Trial is Underway with 1st Patient Implanted at Price Vision Group in Indianapolis on January 30th

Retrieved on: 
Tuesday, February 4, 2020
Surgery, Medical devices, Health, Optical, Clinical trials, Corrective lenses, Medicine, Optics, Medical specialties, Vision, Eye surgery, Ophthalmology, Eye, Intraocular lens, Refractive surgery, Implant, Phakic intraocular lens

Surgeons outside the U.S. have implanted in excess of 750,000 of our EVO lenses in patients as the need for distance vision correction grows.

Key Points: 
  • Surgeons outside the U.S. have implanted in excess of 750,000 of our EVO lenses in patients as the need for distance vision correction grows.
  • We look forward to the U.S. study of our EVO lenses generating additional safety data on our implantable Collamer lenses.
  • The first patient in the U.S. clinical study of EVO implantable lenses was enrolled at Price Vision Group in Indianapolis.
  • STAARs lens used in refractive surgery is called an Implantable Collamer Lens or ICL, which includes the EVO Visian ICL product line.

STAAR Surgical Announces Strategic Alliance Agreement with California Center for Refractive Surgery (CCRS)

Retrieved on: 
Tuesday, December 17, 2019
Health, Optical, Surgery, Eye surgery, Optics, Corrective lenses, Refraction, Refractive surgery, Ophthalmology, Vision, Senses, Perception, Intraocular lens, ICL, Phakic intraocular lens

The ICL is a quick additive procedure that preserves future options by leaving the eye in its most natural state.

Key Points: 
  • The ICL is a quick additive procedure that preserves future options by leaving the eye in its most natural state.
  • This has far-reaching implications for patients in terms of visual outcome and satisfaction, both short term and long term.
  • STAARs lens used in refractive surgery is called an Implantable Collamer Lens or ICL, which includes the EVO Visian ICL product line.
  • California Center for Refractive Surgery (CCRS) was established in 2000 with a mission of providing patients with the most advanced and personalized eye care at an affordable price.

Okayama University Research - Primary Intraocular Lymphoma Does Not Always Spread to the Central Nervous System

Retrieved on: 
Wednesday, December 4, 2019
Lymphoma, Medical specialties, Intraocular lymphoma, Medicine, Branches of biology, Phakic intraocular lens

OKAYAMA, Japan, Dec. 4, 2019 /PRNewswire/ -- Researchers at Okayama University report in the Journal of Clinical and Experimental Hematopathology that primary intraocular lymphoma, a cancer in the eye, does not always develop into central nervous system lymphoma.In addition, the scientists confirmed that there is no marker available to predict when the former will develop into the latter.

Key Points: 
  • OKAYAMA, Japan, Dec. 4, 2019 /PRNewswire/ -- Researchers at Okayama University report in the Journal of Clinical and Experimental Hematopathology that primary intraocular lymphoma, a cancer in the eye, does not always develop into central nervous system lymphoma.In addition, the scientists confirmed that there is no marker available to predict when the former will develop into the latter.
  • Primary intraocular lymphoma (PIOL) is a cancer in the eye originating in lymphocytes, cells of the immune system that fight infections; lymphoma is the condition when lymphocytes grow in an uncontrolled way.Often, PIOL develops into central nervous system lymphoma uncontrolled growth of lymphocytes in the nervous system in the brain and the spinal cord.It is not clear, however, whether this development always occurs.Now, Professor MATSUO Toshihiko(eye doctor) and Assistant Professor TANAKA Takehiro (pathologist) from Okayama University have addressed the question; whether there are PIOLs that do not develop central nervous system lymphoma.They observed a group of patients, and found that in the smallnumber ofcases, PIOL does not spread to the central nervous system.Importantly, PIOL has a good prognosis if it does not develop into central nervous system lymphoma.
  • The scientists also examined whether the presence of a protein called CD5 in specimens taken during vitrectomy surgery are a marker of central nervous system lymphoma.But both patients with CD5-positive and patients with CD5-negative tests developed central nervous system lymphoma, which made Matsuo and Tanaka conclude that "at present, there is no marker available to predict whether a patient with PIOL will develop central nervous system lymphoma."
  • Are there primary intraocular lymphomas that do not develop into central nervous system lymphomas?

Okayama University Research - Primary Intraocular Lymphoma Does Not Always Spread to the Central Nervous System

Retrieved on: 
Wednesday, December 4, 2019
Lymphoma, Medical specialties, Intraocular lymphoma, Medicine, Branches of biology, Phakic intraocular lens

OKAYAMA, Japan, Dec. 4, 2019 /PRNewswire/ -- Researchers at Okayama University report in the Journal of Clinical and Experimental Hematopathology that primary intraocular lymphoma, a cancer in the eye, does not always develop into central nervous system lymphoma.In addition, the scientists confirmed that there is no marker available to predict when the former will develop into the latter.

Key Points: 
  • OKAYAMA, Japan, Dec. 4, 2019 /PRNewswire/ -- Researchers at Okayama University report in the Journal of Clinical and Experimental Hematopathology that primary intraocular lymphoma, a cancer in the eye, does not always develop into central nervous system lymphoma.In addition, the scientists confirmed that there is no marker available to predict when the former will develop into the latter.
  • Primary intraocular lymphoma (PIOL) is a cancer in the eye originating in lymphocytes, cells of the immune system that fight infections; lymphoma is the condition when lymphocytes grow in an uncontrolled way.Often, PIOL develops into central nervous system lymphoma uncontrolled growth of lymphocytes in the nervous system in the brain and the spinal cord.It is not clear, however, whether this development always occurs.Now, Professor MATSUO Toshihiko(eye doctor) and Assistant Professor TANAKA Takehiro (pathologist) from Okayama University have addressed the question; whether there are PIOLs that do not develop central nervous system lymphoma.They observed a group of patients, and found that in the smallnumber ofcases, PIOL does not spread to the central nervous system.Importantly, PIOL has a good prognosis if it does not develop into central nervous system lymphoma.
  • The scientists also examined whether the presence of a protein called CD5 in specimens taken during vitrectomy surgery are a marker of central nervous system lymphoma.But both patients with CD5-positive and patients with CD5-negative tests developed central nervous system lymphoma, which made Matsuo and Tanaka conclude that "at present, there is no marker available to predict whether a patient with PIOL will develop central nervous system lymphoma."
  • Are there primary intraocular lymphomas that do not develop into central nervous system lymphomas?

Toric Implantable Contact Lens Provides Alternative to LASIK Surgery

Retrieved on: 
Monday, July 1, 2019
Optics, Vision, Senses, Perception, Eye surgery, Corrective lenses, LASIK, RTT, Astigmatism, Intraocular lens, Refractive surgery, Phakic intraocular lens

recently placed Iowa's first Visian Toric implantable collamer lens (ICL) manufactured by STAAR Surgical .

Key Points: 
  • recently placed Iowa's first Visian Toric implantable collamer lens (ICL) manufactured by STAAR Surgical .
  • For certain patients, an ICL is considered an alternative to vision correction surgeries such as LASIK, but until this year patients with an astigmatism had fewer options if they found themselves not a candidate for LASIK surgery.
  • "While most patients with astigmatism find great results with LASIK surgery, there are a group of patients that have been told they are not a candidate for any vision correction surgery.
  • The Visian Toric ICL provides these patients a new option," said Dr. Matthew Rauen.